Open-label, multi-centre dose escalation phase I study to investigate the safety and tolerability of a continuous infusion of the bispecific T-cell engager (BiTE) MT110 in locally advanced, recurrent or metastatic solid tumours which commonly express EpCAM.
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2015
At a glance
- Drugs AMG 110 (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms MT110-101
- Sponsors Amgen
- 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 24 Jun 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.